Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
Abstract Background In 2018, meningococcal ACWY-TT vaccine (MenACWY-TT) was offered to adolescents in the Netherlands within the National Immunization Programme at 14 years of age. A questionnaire study assessed the tolerability of this vaccine. Methods Five thousand adolescents were invited to part...
Main Authors: | J. M. Kemmeren, L. van Balveren, A. Kant, H. de Melker |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | BMC Public Health |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12889-021-11767-9 |
Similar Items
-
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years
by: Charissa Fay Corazon Borja-Tabora, et al.
Published: (2020-06-01) -
Information needs during an emerging outbreak of meningococcal W135 disease in the Netherlands: a study among teenagers, their parents and healthcare professionals
by: Marion de Vries, et al.
Published: (2021-08-01) -
A Comprehensive Review of Meningococcal Disease Burden in India
by: Ashok Kumar Dutta, et al.
Published: (2020-07-01) -
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) in Children 9–23 Months of Age in Russian Federation: Results of Russian Part of International Study in Russia and India
by: O. A. Perminova, et al.
Published: (2020-05-01) -
Observational Safety Study of Meningococcal Conjugate Vaccine Against Serogroups A, C, W and Y (Menactra) Used in Routine Healthcare Practice for Persons Aged 2 to 55 Years in Russian Federation
by: I. Ya. Izvekova, et al.
Published: (2019-01-01)